IndustryCompany release

Scribe Therapeutics posts Q3 2026 results after IPO; STX-1150 Phase 1 data due first half 2027

🇺🇸 Scribe Therapeutics, Inc. (SCTX) · Thu 12 Nov 2026

On November 12, 2026, Scribe Therapeutics reported Q3 results, with $174.2 million in cash after a July Nasdaq IPO and concurrent Sanofi private placement raising $155.5 million gross. Enrollment continues in the first-in-human Phase 1 trial of STX-1150, an epigenetic PCSK9-silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027. The company also expanded its Sanofi collaboration to include its ELXR silencing technology and presented preclinical data on STX-1150 and STX-1200 (Lp(a)).

Company's press release (SEC filing): Scribe Therapeutics, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →